JPMorgan, Goldman Short Drugmaker Threatened by Copycat Pills - BusinessWeek

JPMorgan Chase & Co. and Goldman Sachs Group Inc. increased bets against Eisai Co. as the Japanese drugmaker’s best-selling medicine, the Aricept Alzheimer’s disease treatment, loses patent protection.
via businessweek.com

Posted via email from Jack's posterous